Treatment of women with hormone receptor-positive, HER2-negative locally advanced or MBC as initial endocrine-based therapy, or in women who have received prior ET MONALEESA-2
Breast Cancer
Breast Cancer
HR+ HER2-
MONALEESA-2
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Lapatinib
Capecitabine
Capecitabine
Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic settingEGF100151
Breast Cancer
Breast Cancer
HER2+
EGF100151
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
2
Bevacizumab
Paclitaxel
Paclitaxel
First-line treatment of adult patients with metastatic breast cancerE2100
Breast Cancer
Breast Cancer
-
E2100
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
2
Everolimus
Exemestane
Exemestane + placebo
Treatment of HR+, HER2- advanced breast cancer, in combination with exemestane, in postmenpausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitorBOLERO-2
Breast Cancer
Breast Cancer
HR+ HER2-
BOLERO-2
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
2
Eribulin
-
Treatment of physician's choice
As monotherapy for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after ≥1 ChT regimen for advanced diseaseEMBRACE
Breast Cancer
Breast Cancer
-
EMBRACE
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
2
Eribulin
-
Treatment of physician's choice
Treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatmentsStudy 305 & Study 301 (Pooled analysis)
Breast Cancer
Breast Cancer
HER2-
Study 305 & Study 301 (Pooled analysis)
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
1
Panitumumab
FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)
FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)
First-line treatment of patients with wild-type RAS mCRC PRIME
Treatment of patients with EGFR-expressing, RAS wild-type mCRC CRYSTAL
Gastrointestinal Cancers
Colorectal Cancer
EGFR-expressing RAS-WT
CRYSTAL
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Cetuximab
-
Best supportive care
Treatment of patients with EGFR-expressing, RAS wild-type mCRC in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan CO.17
Treatment of patients with metastatic carcinoma of the colon or rectum E3200
Gastrointestinal Cancers
Colorectal Cancer
-
E3200
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
3
Panitumumab
-
Best supportive care
Treatment of patients with wild-type RAS mCRC after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing ChT regimens Study 20020408
Gastrointestinal Cancers
Colorectal Cancer
RAS-WT
Study 20020408
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
2
Oxaliplatine
FOLFOXIRI + bevacizumab
FOLFIRI + bevacizumab
Treatment of patients with metastatic carcinoma of the colon or rectum TRIBE
Gastrointestinal Cancers
Colon and Rectal Cancer
-
TRIBE
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
2
Regorafenib
-
Placebo
Treatment of patients with mCRC who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based ChT, an anti-VEGF therapy and an anti-EGFR therapy CORRECT
Gastrointestinal Cancers
Colorectal Cancer
-
CORRECT
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
1
Aflibercept
FOLFIRI
FOLFIRI + placebo
Metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin containing regimenVELOUR
Gastrointestinal Cancers
Colorectal Cancer
-
VELOUR
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
1
Bevacizumab
Chemotherapy
Chemotherapy
Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based ChT for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen ML18147
Gastrointestinal Cancers
Colon and Rectal Cancer
-
ML18147
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
1
Epirubicin, 5-FU, Cisplatin + surgery
-
Surgery
Peri-operative resectable gastric or gastroesophageal junction adenocarcinomaMAGIC
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
MAGIC
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F1
A
5-FU + cisplatin + surgery
-
Surgery
Peri-operative resectable gastric or gastroesophageal junction adenocarcinomaFRE-FNCLCC-94012
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
FRE-FNCLCC-94012
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F1
A
Ramucirumab
Paclitaxel
Paclitaxel + placebo
Advanced gastric cancer or gastroesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine ChTRAINBOW
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
RAINBOW
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
2
Ramucirumab
-
Placebo
Treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine ChT, when treatment in combination with paclitaxel is not appropriateREGARD
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
REGARD
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
1
FOLFIRINOX
-
Gemcitabine
First-line metastatic pancreatic cancer in patients with good performance statusPRODIGE 4/ACCORD 11
Gastrointestinal Cancers
Pancreatic cancer
-
PRODIGE 4/ACCORD 11
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
5
Nab-paclitaxel
Gemcitabine
Gemcitabine
Nab-paclitaxel in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreasMPACT
Gastrointestinal Cancers
Pancreatic cancer
-
MPACT
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
3
Erlotinib
Gemcitabine
Gemcitabine + placebo
Erlotinib in combination with gemcitabine for the treatment of patients with metastatic pancreatic cancerPA.3
Gastrointestinal Cancers
Pancreatic cancer
-
PA.3
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
1
Bevacizumab
Combination chemotherapy
Combination chemotherapy
In combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervixGOG 240
Gynaecological Malignancies
Cervical Cancer
-
GOG 240
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
3
Bevacizumab
Chemotherapy
Paclitaxel or topotecan or liposomal doxorubicin
In combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube,or primary peritoneal cancer who received ≤2 prior ChT regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agentsAURELIA
Gynaecological Malignancies
Ovarian Cancer
-
AURELIA
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Bevacizumab
Paclitaxel + carboplatin
Paclitaxel + carboplatin
In combination with carboplatin and paclitaxel for the front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancerICON7
Gynaecological Malignancies
Ovarian Cancer
-
ICON7
1
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
1
Bevacizumab
Gemcitabine + carboplatin
Gemcitabine + carboplatin
In combination with carboplatin and gemcitabine for treatment of adult patients with first recurrence platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agentsOCEANS
Gynaecological Malignancies
Ovarian Cancer
-
OCEANS
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
3
Bevacizumab
Carboplatin + paclitaxel
Paclitaxel + carboplatin (6 cycles)
Front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. GOG-0218
Gynaecological Malignancies
Ovarian Cancer
-
GOG-0218
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
3
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.